Based on the Lipocine Inc stock forecast from 1 analysts, the average analyst target price for Lipocine Inc is USD 6.75 over the next 12 months. Lipocine Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Lipocine Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Lipocine Inc’s stock price was USD 3.06. Lipocine Inc’s stock price has changed by -3.47% over the past week, -11.05% over the past month and -46.97% over the last year.
No recent analyst target price found for Lipocine Inc
No recent average analyst rating found for Lipocine Inc
Company Overview Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. Read Less
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprisin...Read More
Frequently Asked Questions About Lipocine Inc (LPCN) Stock
Based on ratings from 1 analysts Lipocine Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on LPCN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for LPCN is USD 6.75 over the next 12 months. The maximum analyst target price is USD 6.75 while the minimum anlayst target price is USD 6.75.
Unfortunately we do not have enough data on LPCN's stock to indicate if its overvalued.
The last closing price of LPCN's stock was USD 3.06.
The most recent market capitalization for LPCN is USD 0.02B.
Based on targets from 1 analysts, the average taret price for LPCN is projected at USD 6.75 over the next 12 months.
This means that LPCN's stock price may go up by +120.59% over the next 12 months.
We can't find any ETFs which contains Lipocine Inc's stock.
As per our most recent records Lipocine Inc has 16 Employees.
Lipocine Inc's registered address is 675 Arapeen Drive, Salt Lake City, UT, United States, 84108.
You can get more information about it from Lipocine Inc's website at https://www.lipocine.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Lipocine Inc (LPCN) Stock
Based on ratings from 1 analysts Lipocine Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on LPCN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for LPCN is USD 6.75 over the next 12 months. The maximum analyst target price is USD 6.75 while the minimum anlayst target price is USD 6.75.
Unfortunately we do not have enough data on LPCN's stock to indicate if its overvalued.
The last closing price of LPCN's stock was USD 3.06.
The most recent market capitalization for LPCN is USD 0.02B.
Based on targets from 1 analysts, the average taret price for LPCN is projected at USD 6.75 over the next 12 months.
This means that LPCN's stock price may go up by +120.59% over the next 12 months.
We can't find any ETFs which contains Lipocine Inc's stock.
As per our most recent records Lipocine Inc has 16 Employees.
Lipocine Inc's registered address is 675 Arapeen Drive, Salt Lake City, UT, United States, 84108.
You can get more information about it from Lipocine Inc's website at https://www.lipocine.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LPCN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
